BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wongsaengsak S, Kopel J, Behera TR, Chakraborty R, Ball S. Infection risk with carfilzomib in multiple myeloma: a systematic review and meta-analysis of randomised controlled trials. Br J Haematol 2020;190:e95-7. [PMID: 32400886 DOI: 10.1111/bjh.16735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Georgoulis V, Haidich A, Bougioukas KI, Hatzimichael E. Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews. Critical Reviews in Oncology/Hematology 2022;180:103842. [DOI: 10.1016/j.critrevonc.2022.103842] [Reference Citation Analysis]
2 Encinas C, Hernandez-Rivas JÁ, Oriol A, Rosiñol L, Blanchard MJ, Bellón JM, García-Sanz R, de la Rubia J, de la Guía AL, Jímenez-Ubieto A, Jarque I, Iñigo B, Dourdil V, de Arriba F, Pérez-Ávila CC, Gonzalez Y, Hernández MT, Bargay J, Granell M, Rodríguez-Otero P, Silvent M, Cabrera C, Rios R, Alegre A, Gironella M, Gonzalez MS, Sureda A, Sampol A, Ocio EM, Krsnik I, García A, García-Mateo A, Soler JA, Martín J, Arguiñano JM, Mateos MV, Bladé J, San-Miguel JF, Lahuerta JJ, Martínez-López J; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer J 2022;12:68. [PMID: 35440057 DOI: 10.1038/s41408-022-00652-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]